Abstract
The deep lungs provide an efficient pathway for drugs to transport into the systemic circulation, as the extremely large surface area and thin epithelial membrane enable rapid drug transport to the blood stream. To penetrate into the deep lungs, aerosol particles with aerodynamic diameters of 1-3 m are optimal. Large porous hollow particles (LPHPs) can achieve this aerodynamic size range through enhanced porosity within the particles (typically < 0.4 g/cm3), which aerodynamically balances the large particle size (> 5 µm, up to 30 µm). The physical properties of these particles provide some key advantages compared to their small, nonporous counterparts through enhanced dispersibility, efficient deep lung deposition, and avoidance of phagocytic clearance. This review highlights the potential of LPHPs in pulmonary delivery of systemic drugs, with a focus on their critical attributes and key formulation aspects. In addition, three examples of LPHPs under development are presented to emphasize the potential of this technology to treat systemic diseases.
Keywords: PulmoSpheres, nanoparticle aggregates, porosity, dispersibility, aerodynamic diameter, systemic circulation.
Current Pharmaceutical Design
Title:Large Porous Hollow Particles: Lightweight Champions of Pulmonary Drug Delivery
Volume: 22 Issue: 17
Author(s): Sachin Gharse and Jennifer Fiegel
Affiliation:
Keywords: PulmoSpheres, nanoparticle aggregates, porosity, dispersibility, aerodynamic diameter, systemic circulation.
Abstract: The deep lungs provide an efficient pathway for drugs to transport into the systemic circulation, as the extremely large surface area and thin epithelial membrane enable rapid drug transport to the blood stream. To penetrate into the deep lungs, aerosol particles with aerodynamic diameters of 1-3 m are optimal. Large porous hollow particles (LPHPs) can achieve this aerodynamic size range through enhanced porosity within the particles (typically < 0.4 g/cm3), which aerodynamically balances the large particle size (> 5 µm, up to 30 µm). The physical properties of these particles provide some key advantages compared to their small, nonporous counterparts through enhanced dispersibility, efficient deep lung deposition, and avoidance of phagocytic clearance. This review highlights the potential of LPHPs in pulmonary delivery of systemic drugs, with a focus on their critical attributes and key formulation aspects. In addition, three examples of LPHPs under development are presented to emphasize the potential of this technology to treat systemic diseases.
Export Options
About this article
Cite this article as:
Gharse Sachin and Fiegel Jennifer, Large Porous Hollow Particles: Lightweight Champions of Pulmonary Drug Delivery, Current Pharmaceutical Design 2016; 22 (17) . https://dx.doi.org/10.2174/1381612822666160128145356
DOI https://dx.doi.org/10.2174/1381612822666160128145356 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Linkage “Body Mass Index-Insomnia Levels-Eating Disorder Flexibility”
in Italian Nurses During the Covid-19 Outbreak: A Psychoendocrinological
Employment Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets 12-Lipoxygenase: A Potential Target for Novel Anti-Platelet Therapeutics
Cardiovascular & Hematological Agents in Medicinal Chemistry Advances in Anticancer Antibody-Drug Conjugates and Immunotoxins
Recent Patents on Anti-Cancer Drug Discovery Thiol Proteases: Inhibitors and Potential Therapeutic Targets
Current Medicinal Chemistry On the Genetics of Innate Immunity in Crohns Disease
Current Genomics Anabolics in Osteoporosis: The Emerging Therapeutic Tool
Current Molecular Medicine Current State of Development of Genome Analysis in Livestock
Current Genomics Rheumatoid Arthritis Patients with Sjogrens Syndrome are More Prone to Depression than Patients with Rheumatoid Arthritis or Sjogrens Syndrome Alone
Current Rheumatology Reviews Nanotechnology can Provide Therapeutic Agent by Targeting Molecular Structures of SARS-CoV-2 (COVID-19): A Mini-Review
Letters in Drug Design & Discovery Evaluation of Isolated Fractions of Aloe vera Gel Materials on Indinavir Pharmacokinetics: In vitro and in vivo Studies
Current Drug Delivery Synthesis and Screening of N-Alkyl Hydroxamates for Inhibition of Cancer Cell Proliferation
Combinatorial Chemistry & High Throughput Screening Bone and the Kidney: A Systems Biology Approach to the Molecular Mechanisms of Renal Osteodystrophy
Current Molecular Medicine Clinical Trajectories and Biological Features of Primary Progressive Aphasia (PPA)
Current Alzheimer Research Peptide-Based Inhibitors of the HIV Envelope Protein and Other Class I Viral Fusion Proteins
Current Pharmaceutical Design The Dual Role of Tumor Necrosis Factor (TNF) in Cancer Biology
Current Medicinal Chemistry Stress as a Pathophysiological Factor in Functional Somatic Syndromes
Current Psychiatry Reviews Episensitization: Therapeutic Tumor Resensitization by Epigenetic Agents: A Review and Reassessment
Anti-Cancer Agents in Medicinal Chemistry Roles of p38-MAPK in Insulin Resistant Heart: Evidence from Bench to Future Bedside Application
Current Pharmaceutical Design Fragile X Syndrome and Autism: Common Developmental Pathways?
Current Pediatric Reviews Glucose Oncometabolism of Esophageal Cancer
Anti-Cancer Agents in Medicinal Chemistry